MFS.V - Medifocus Inc.

TSXV - TSXV Delayed Price. Currency in CAD

Medifocus Inc.

The Exchange Tower
PO Box 427 130 King Street West Suite 1800
Toronto, ON M5X 1E3
Canada
905-319-7070
http://www.medifocusinc.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees7

Key Executives

NameTitlePayExercisedYear Born
Dr. William W. JowCEO, Pres & Director174kN/A1958
Mr. Mirsad Jakubovic C.A., M.B.A.Chief Financial OfficerN/AN/A1962
Mr. John MonVP of Regulatory Affairs & Product Devel.N/AN/A1953
Mr. Douglas LiuVP of Fin.N/AN/A1964
Dr. Stuart E. Katz M.D.VP of OperationsN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

Medifocus Inc., a medical technology company, develops and commercializes minimally invasive focused heat systems for the treatment of cancerous and benign tumors, and enlarged prostate in Canada and the United States. The company owns technology platforms, including Endo-thermotherapy platform, a catheter-based focused heat technology platform that utilizes natural body openings to deliver microwave thermotherapy to the diseased sites; and Adaptive Phased Array (APA) Microwave Focusing platform, which directs focused microwave energy at tumor center to induce shrinkage or eradication of tumors without undue harm to surrounding tissue. It also offers Prolieve Thermodilatation system, a medical device based on endo-thermotherapy for the treatment of benign prostatic hyperplasia. In addition, the company is developing APA 1000, a minimally invasive breast cancer treatment system, which is in pivotal Phase-III clinical trials. The company has a license agreement with Duke University for the development of heat-activated and tumor-targeted immunotherapy and gene therapy technology for the treatment of cancers and other diseases. Medifocus Inc. has a patent license agreement with Duke University for the development of heat-activated and tumor-targeted immunotherapy and gene therapy for the treatment of cancers and other diseases. The company is based in Toronto, Canada.

Corporate Governance

Medifocus Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.